Search results for "STIMA"

showing 10 items of 1809 documents

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

2019

Abstract Background This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. Methods 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of patients were at poor risk, intermediate and favorable risk, respectively. Results PFS, OS, DCR and ORR were 7.14 months, 15.5 months, 70.6% and 16.6%, respectively. The duration of prior sunitinib treatment correlated with a longer significant mPFS, 8.8 vs 6.3 months, respectively. Axitinib therapy was safe, without grade 4 adverse events. The most frequent toxicities of all grades were: fati…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisAxitinibAxitinib; Metastatic; Renal cancer; Sunitinib; Treatmentmedicine.medical_treatmentPopulationlcsh:MedicineKaplan-Meier EstimateDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineSunitinibHumansMedicineNeoplasm MetastasiseducationAdverse effectMetastatic renal cell cancerCarcinoma Renal CellAgedAged 80 and overSecond-line therapyeducation.field_of_studybusiness.industrySunitinibResearchlcsh:RGeneral MedicineMiddle AgedKidney NeoplasmsNephrectomyAxitinibTreatment030104 developmental biologyRenal cancer030220 oncology & carcinogenesisMultivariate AnalysisMetastaticFemalebusinessmedicine.drugJournal of Translational Medicine
researchProduct

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

2016

This analysis confirms that administering neoadjuvant chemotherapy (NACT) before chemoradiotherapy (CRT) could be a potential option for high-risk, locally advanced rectal cancer. In this setting, MRI tumour regression grade is an independent prognostic factor and, when assessed after NACT, may predict the probability and magnitude of incremental benefit from sequential CRT.EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC). We pooled individual patient data from these trials. The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Pro…

AdultMale0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentPopulationPhases of clinical researchKaplan-Meier EstimateDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProgression-free survivalStage (cooking)educationNeoadjuvant therapyAgedAged 80 and overeducation.field_of_studyIntention-to-treat analysisRectal Neoplasmsbusiness.industrySurrogate endpointChemoradiotherapyHematologyMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessChemoradiotherapy
researchProduct

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before an…

2020

Rossella Parini,1,2 Guillem Pintos-Morell,3 Julia B Hennermann,4 Ting-Rong Hsu,5 Nesrin Karabul,6 Vasiliki Kalampoki,7 Andrey Gurevich,7 Uma Ramaswami8 On behalf of the FOS Study Group1Rare Metabolic Diseases Unit, MBBM Foundation, San Gerardo Hospital, Reference Centre for Hereditary Metabolic Disorders (MetabERN), Monza, Italy; 2TIGET Institute, IRCCS San Raffaele Hospital, Milan, Italy; 3Division of Rare Diseases, Reference Centre for Hereditary Metabolic Disorders (MetabERN), University Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain; 4Villa Metabolica, Department of Pediatric and Adolescent Medicine, University Medical Center, Mainz, Germany; 5Dep…

AdultMale0301 basic medicinemedicine.medical_specialtyestimated glomerular filtration rateAdolescentPharmaceutical ScienceRenal functionLeft ventricular hypertrophyFabry Outcome SurveyYoung Adult03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineHumansEnzyme Replacement TherapyEstimated glomerular filtration rateChildAgalsidase alfaOriginal ResearchRetrospective StudiesPharmacologyagalsidase alfaFabry diseaseProteinuriaDrug Design Development and Therapybusiness.industryLeft ventricular hypertrophyEnzyme replacement therapyMiddle Agedmedicine.diseaseFabry diseaseRecombinant Proteinsleft ventricular hypertrophyIsoenzymesTreatment Outcome030104 developmental biologyMale patientalpha-Galactosidase030220 oncology & carcinogenesisEnzyme replacement therapyCohortmedicine.symptombusinessAgalsidase alfa
researchProduct

Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-cen…

2015

Abstract Objectives Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that has been reported worldwide for the last two decades. The aim of this study is to analyse the clinical profile of patients from Spain with AIP, as well as treatments, relapses and long-term outcomes. Methods Data from 59 patients with suspected AIP that had been diagnosed in 15 institutions are retrospectively analysed. Subjects are classified according to the International Consensus Diagnostic Criteria (ICDC). Patients with type 1 AIP (AIP1) and type 2 AIP (AIP2) are compared. Kaplan–Meier methodology is used to estimate the overall survival without relapses. Results Fifty-two patients met ICDC, 45 pat…

AdultMaleAbdominal painmedicine.medical_specialtyPathologyConsensusEndocrinology Diabetes and MetabolismKaplan-Meier EstimateDisease-Free SurvivalAutoimmune Diseases03 medical and health sciences0302 clinical medicineInternal medicinePancreatitis ChronicmedicineCombined Modality TherapyHumansPancreatitis chronicMulti centreAutoimmune pancreatitisAgedRetrospective StudiesHepatologybusiness.industryGastroenterologyRetrospective cohort studyMiddle Agedmedicine.diseaseCombined Modality TherapyTreatment OutcomeDiagnosis treatmentSpain030220 oncology & carcinogenesisPractice Guidelines as TopicPancreatitis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessFollow-Up StudiesPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
researchProduct

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.

2016

We investigated a possible interaction between age-associated risk and HLA-mismatch associated risk on prognosis in different age categories of recipients of unrelated hematopoietic stem cell transplants (HSCT) (n=3019). Patients over 55 years of age transplanted with 8/10 donors showed a mortality risk of 2.27 (CI 1.70–3.03, P<0.001) and 3.48 (CI 2.49–4.86, P<0.001) when compared to 10/10 matched patients in the same age group and to 10/10 matched patients aged 18–35 years, respectively. Compared to 10/10 matched transplantations within each age category, the Hazards Ratio for 8/10 matched transplantation was 1.14, 1.40 and 2.27 in patients aged 18–35 years, 36–55 and above 55 years. Model…

AdultMaleAdolescentmedicine.medical_treatmentAge categoriesHematopoietic stem cell transplantationHuman leukocyte antigenHistocompatibility TestingKaplan-Meier Estimate03 medical and health sciencesYoung Adult0302 clinical medicineHLA AntigensRisk FactorsCell Therapy & ImmunotherapymedicineHumansPublic Health SurveillanceYoung adultMortalityAgedbusiness.industryHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationHematopoietic stem cellHematologyArticlesMiddle Aged3. Good healthHistocompatibilitysurgical procedures operativemedicine.anatomical_structure030220 oncology & carcinogenesisHistocompatibilityImmunologyFemalebusinessUnrelated Donors030215 immunologyHaematologica
researchProduct

Usefulness of combining clinical and radiological dental findings for a more accurate noninvasive age estimation.

2007

: The aim of this study was to establish correlations of clinical and radiological dental findings, alone or in combination, with chronological age in adults. Dental findings and orthopantomograms of 984 patients (aged 20–60 years; 524 females/460 males) were analyzed. DMF-T index and distance (alveolar bone level, ABL) between cemento-enamel junction and alveolar bone margin were recorded. Additionally, clinical and radiological findings at each tooth crown and root were collected according to the actual status of destruction and restoration, and a total score for each dentition (TSD) was calculated. After univariate correlation analysis, correlation coefficients for ABL and TSD were impro…

AdultMaleAlveolar Bone LossDentistryDental CariesTooth crownPathology and Forensic MedicineCorrelationstomatognathic systemRadiography PanoramicGeneticsMedicineHumansTooth RootDental alveolusTooth CrownSex CharacteristicsDentitionbusiness.industryUnivariateMiddle AgedDentition Permanentstomatognathic diseasesAge estimationRadiological weaponCorrelation analysisRegression AnalysisFemaleAge Determination by TeethbusinessForensic DentistryJournal of forensic sciences
researchProduct

Convex rear view mirrors compromise distance and time-to-contact judgements

2007

Convex rear view mirrors increasingly replace planar mirrors in automobiles. While increasing the field of view, convex mirrors are also taken to increase distance estimates and thereby reduce safety margins. However, this study failed to replicate systematic distance estimation errors in a real world setting. Whereas distance estimates were accurate on average, convex mirrors lead to significantly more variance in distance and spacing estimations. A second experiment explored the effect of mirrors on time-to-contact estimations, which had not been previously researched. Potential effects of display size were separated from effects caused by distortion in convex mirrors. Time-to-contact est…

AdultMaleAutomobile DrivingEngineeringTime FactorsAdolescentRear-view mirrorPoison controlCurved mirrorPhysical Therapy Sports Therapy and RehabilitationHuman Factors and ErgonomicsField of viewOpticsDistortionHumansComputer SimulationSimulationPerceptual Distortionbusiness.industryEstimation theoryDistance PerceptionProtective DevicesMiddle AgedStopping sight distanceMotor VehiclesFemaleErgonomicsVisual FieldsVisual anglebusinessErgonomics
researchProduct

Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multi…

2015

This phase 1/2 study was the first to evaluate the safety and efficacy of the cyclin-dependent kinase (CDK) 4/6-specific inhibitor palbociclib (PD-0332991) in sequential combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. The recommended phase 2 dose was palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (intravenous) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 (early G1 arrest) and days 15 and 18 (cell cycle resumed). Dose-limiting toxicities were primarily cytopenias; most other treatment-related adverse events were grade≤3. At a bortezomib dose lower than that in other combina…

AdultMaleCancer ResearchCombination therapyPyridinesKaplan-Meier EstimatePalbociclibPharmacologyDexamethasoneDrug Administration SchedulePiperazinesBortezomibRecurrenceCyclin-dependent kinaseAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineMultiple myelomaDexamethasoneAgedNeoplasm StagingAged 80 and overbiologybusiness.industryBortezomibCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HematologyMiddle AgedCell cyclemedicine.diseaseTreatment OutcomeOncologyDrug Resistance NeoplasmPharmacodynamicsRetreatmentbiology.proteinFemaleDrug MonitoringMultiple Myelomabusinessmedicine.drugLeukemia &amp; Lymphoma
researchProduct

Cancer net survival on registry data: use of the new unbiased Pohar-Perme estimator and magnitude of the bias with the classical methods

2013

Net survival, the survival which might occur if cancer was the only cause of death, is a major epidemiological indicator required for international or temporal comparisons. Recent findings have shown that all classical methods used for routine estimation of net survival from cancer-registry data, sometimes called "relative-survival methods," provide biased estimates. Meanwhile, an unbiased estimator, the Pohar-Perme estimator (PPE), was recently proposed. Using real data, we investigated the magnitude of the errors made by four "relative-survival" methods (Ederer I, Hakulinen, Ederer II and a univariable regression model) vs. PPE as reference and examined the influence of time of follow-up,…

AdultMaleCancer ResearchLung NeoplasmsAdolescent[SDV]Life Sciences [q-bio]Breast NeoplasmsRisk Assessment03 medical and health sciencesAge Distribution0302 clinical medicineBreast cancerBiasBias of an estimatorRisk FactorsCause of DeathNeoplasmsStatisticsmedicineHumansRegistriesThyroid Neoplasms030212 general & internal medicineSurvival analysisAgedMathematicsEstimationModels StatisticalRelative survivalIncidenceAge FactorsProstatic NeoplasmsCancerEstimatorRegression analysisMiddle AgedPrognosismedicine.diseaseHodgkin DiseaseSurvival Analysis3. Good healthOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisFemaleFranceColorectal Neoplasms
researchProduct

Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular…

2013

Cholangiocellular carcinoma (CCA) is a primary hepatic malignancy derived from cholangiocytes. The prognosis for CCA patients is very poor and conventional chemotherapy has been proven ineffective in improving long‑term patient survival rates. Organic cation transporters (OCTs) mediate the transport of a broad spectrum of endogenous substrates and the detoxification of xenobiotics. Moreover, OCTs are considered responsible for the responsiveness towards platinum‑based chemotherapies. Currently, there are no data available regarding the role of OCTs in CCA. Therefore, the aim of this study was to investigate the expression of OCT1 and OCT3 in CCA and the corresponding non-neoplastic tumor‑su…

AdultMaleCancer ResearchOrganic Cation Transport ProteinsDown-RegulationKaplan-Meier EstimateBiologySLC22A3CholangiocarcinomaDownregulation and upregulationWestern blotmedicineHumansRNA MessengerAgedAged 80 and overOncogenemedicine.diagnostic_testOrganic Cation Transporter 1CancerMiddle Agedmedicine.diseaseMolecular medicineBile Ducts IntrahepaticBile Duct NeoplasmsOncologyTumor progressionDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleNeoplasm Recurrence LocalInternational Journal of Oncology
researchProduct